BiotechTube

Imipenem

ApprovedUNKNOWN
0 watching 0 views this week🔥 Hot
85
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Sepsis

Conditions

Sepsis

Trial Timeline

Jan 1, 2015 → Dec 1, 2015

NCT ID
NCT02616354

About Imipenem

Imipenem is a approved stage product being developed by Merck for Sepsis. The current trial status is unknown. This product is registered under clinical trial identifier NCT02616354. Target conditions include Sepsis.

Hype Score Breakdown

Clinical
30
Activity
20
Company
10
Novelty
10
Community
12

Clinical Trials (1)

NCT IDPhaseStatus
NCT02616354ApprovedUNKNOWN

Competing Products

20 competing products in Sepsis

See all competitors
ProductCompanyStageHype Score
Alkaline Phosphatase + PlaceboAM-PharmaPhase 2
44
Drotrecogin alfa (activated)Eli LillyPhase 2
52
MeropenemPfizerApproved
84
CefiderocolShionogiPhase 1
33
eritoran tetrasodium + PlaceboEisaiPhase 3
77
E5564EisaiPhase 2
52
Drotrecogin Alfa (Activated) + placeboEli LillyPhase 3
77
Drotrecogin alfa (activated) + PlaceboEli LillyPhase 3
77
Drotrecogin Alfa (activated)Eli LillyApproved
85
Drotrecogin alfa (activated) + PlaceboEli LillyPhase 3
77
Drotrecogin alfa (activated) + PlaceboEli LillyPhase 3
77
sPLA2 InhibitorEli LillyPhase 1/2
41
Drotrecogin alfa (activated)Eli LillyApproved
85
Drotrecogin Alfa (Activated) + Unfractionated heparin + Low molecular weight heparinEli LillyApproved
85
drotrecogin alfa (activated)Eli LillyApproved
85
drotrecogin alfa (activated)Eli LillyApproved
85
AZD9773 (CytoFab)AstraZenecaPhase 2
52
AZD9773 + PlaceboAstraZenecaPhase 2
52
AZD9773 + PlaceboAstraZenecaPhase 2
52
AZD4144 + PlaceboAstraZenecaPhase 2
52

Other Products from Merck

DuleraApproved
85
Mavenclad®Approved
85
raltegravir + PlaceboApproved
85
alendronate sodiumApproved
85
Fidaxomicin + VancomycinApproved
85